Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives.

Annals of hematology - 1 Mar 1996

Hegewisch-Becker S, Hossfeld D K

Abstract excerpt

The multidrug resistant (MDR) phenotype has been suspected as a major cause of treatment failure in hematologic malignancies. Numerous studies have investigated the expression of the MDR1 gene product, P-glycoprotein, in leukemia, lymphoma and myeloma. Studies in myelogenous leukemia and myeloma have so far provided best evidence for a significant correlation between P-glycoprotein expression and response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Multiple
Share to Forecasting
Share to Gene Expression

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia

Share to Lymphoma

Share to Multiple Myeloma

Share to Phenotype

Share to Prognosis

Source

Identifiers

PMID: 8766251
DOI: 10.1007/s002770050147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives.PMID 8766251Read ↗

Classical multidrug resistance in acute myeloid leukaemia.Semantic proximity Read ↗

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype.Semantic proximity Read ↗

Multidrug resistance in oncology: diagnostic and therapeutic approachesSemantic proximity Read ↗

What does Multidrug Resistance (MDR) Expression Mean in the Clinic?Semantic proximity Read ↗

MDR1 in immunity: friend or foe?Semantic proximity Read ↗

Multidrug resistance in leukemiaSemantic proximity Read ↗

The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemiaSemantic proximity Read ↗

Multidrug resistance in acute myeloid leukaemia.Semantic proximity Read ↗

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.Semantic proximity Read ↗

Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategiesSemantic proximity Read ↗

P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications.Semantic proximity Read ↗

Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.